Close menu




August 24th, 2020 | 07:58 CEST

Apple, Scottie Resources, Tesla - where do investments make sense now?

  • Investments
Photo credits: pixabay.com

The shares of the largest companies in the world promise high liquidity. Companies with technologies are the focus of investors - especially among the younger generation. So it is hardly surprising that the measures taken by the central banks are leading to a flight from money to shares in companies. Company shares that are very tradable and backed by dividends or profits can be more valuable in the end than the bond of a heavily debt-driven state or its paper money, which could be multiplied virtually endlessly. The situation in the commodities sector is becoming increasingly exciting, as physical gold is in greater demand than ever before, but most investors are not yet focusing on this sector.

time to read: 2 minutes | Author: Mario Hose
ISIN: US88160R1014 , US0378331005 , CA81012R1064

Table of contents:


    Battery cars are part of the problem

    Elon Musk is celebrated at the stock markets. You can't really explain it. Where would the company stand today without environmental bonuses and subsidies? In Berlin the creation of jobs and the settlement of further companies is hailed by the new Tesla plant, while elsewhere the lights go out. The battery as an energy storage device is controversial and the energy mix in Germany is not designed for electric mobility.

    In June 2020, the Institute for World Economy published a study that shows the increase in CO2 emissions for every additional electricity consumer. While a modern diesel is at 173 g CO2 per kilometer, a battery car emits 300 g CO2 per kilometer. In 2019, Tesla generated USD 780.06 per second in sales. Compared to the leader Volkswagen with 9,202.88 USD per second, this value is very low. It is doubtful whether an innovation that is only appealing with taxpayers' money can survive in the long run.

    Golden times have begun

    Anyone interested in the oldest currency in the world should take a look at the value added. Scottie Resources from Canada owns the former producing Scottie gold mine and other properties as well as the option to acquire claims adjacent to the Scottie gold mine property. In total, the exploration company owns 24,589 hectares of properties in British Columbia's Golden Triangle, one of the most productive mineralized areas in the world.

    Bradley Rourke, the company's CEO, recently issued a news release providing insight into the Company's development: "With our strong financial position, favourable market conditions and abundance of drill targets, we have decided to increase the metres drilled this summer. The addition of a second drill rig allows us to test new prospective zones and improve the cost efficiency of drilling additional metres given that all the infrastructure and personnel are already in place."

    The company has now added a second drill rig to its Scottie Gold Project, which will increase the number of holes drilled by 40%, an additional 2,000 metres for the drilling program. A total of 7,000 metres of drilling is now targeted for the 2020 summer season. The current drill program will follow up on the successful work of the 2019 season when intercepts of 7.44 g/t gold over 34.78 m at the Blueberry Vein, 11.72 g/t gold over 10.95 m at the past producing Scottie Gold Mine, and 73.32 g/t gold over 4.38 m at the Bend Vein were discovered.

    The air is getting thinner

    While Scottie Resources' investors are likely to see a higher share price if the drilling program continues to be successful, Apple's investors should slowly be aware that the trees can no longer grow to the sky. It remains to be seen what impact the global economic downturn will have on consumer behavior. After all, Apple devices are expensive and high-quality premium products and some customers might be tiring out their lifespan in times of the Corona pandemic - and forego buying a new one.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read